IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandava, N.
Right arrow Articles by Kruse, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandava, N.
Right arrow Articles by Kruse, C. A.
(Investigative Ophthalmology and Visual Science. 2002;43:3338-3348.)
© 2002 by The Association for Research in Vision and Ophthalmology, Inc.

Ribozyme to Proliferating Cell Nuclear Antigen to Treat Proliferative Vitreoretinopathy

Naresh Mandava1, Peter Blackburn1, David B. Paul2, Matthew W. Wilson3, Susana B. Read2, Eric Alspaugh4, Richard Tritz4, Jack R. Barber4, Joan M. Robbins4 and Carol A. Kruse2,5

1 From the Departments of Ophthalmology, 2 Immunology, and 5 Pathology, University of Colorado Health Science Center, Denver, Colorado; the 3 Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee; and 4 Immusol, Inc., San Diego, California.

PURPOSE. A DNA-RNA chimeric ribozyme was developed that targets the mRNA of a cell cycle regulatory protein, proliferating cell nuclear antigen (PCNA). The hypothesis was that inhibition of PCNA, essential in DNA replication, would decrease the proliferation of cells that are involved in formation of granuloma after surgical procedures in the eye. The ability of intravitreous injection of this ribozyme to prevent or inhibit development of proliferative vitreoretinopathy (PVR) was tested in a dispase-induced rabbit PVR model.

METHODS. Rabbit genomic DNA encoding PCNA was cloned and sequenced. The cleavage of rabbit PCNA by the chimeric ribozyme was tested in vitro. Delivery of the ribozyme to rabbit retinal pigment epithelial (RPE) or fibroblast cells and its effects on proliferation of fibroblasts were examined. The stability of the ribozyme in vitreous fluid and serum was studied as well. In the dispase-induced rabbit model of PVR, the ability of the PCNA ribozyme to prevent or inhibit development of PVR and retinal detachment (RD) was tested. Experimental groups receiving intravitreous PCNA ribozyme, with or without a lipid vehicle, were compared with sham-treated control groups. Progression of PVR in rabbit eyes was followed by indirect ophthalmic examination and observations documented by fundoscopic photography, gross pathology, and histopathology.

RESULTS. The chimeric ribozyme targeted a specific sequence in the rabbit PCNA that was identical with that in the human. In vitro cleavage assays confirmed the ability of the ribozyme to cleave the mRNA of PCNA. The catalytic efficiency in vitro, calculated as k2/Kmapp, was 0.26 µM-1 min-1. In vitro studies with fluoresceinated ribozyme indicated that lipid vehicles facilitated delivery of the ribozyme into cells causative of PVR (RPE and fibroblasts); however, the PCNA ribozyme decreased the proliferation of fibroblasts, with or without lipid vehicle. The ribozyme displayed good stability in vitreous fluid, whereas, it degraded quite rapidly in serum. In animal experiments, rabbits in sham-treated groups usually exhibited development of severe PVR characterized by focal traction or RD. Animals in the PCNA ribozyme–treated groups usually did not exhibit an RD. If they did have RD, it was small and localized, or focal tractions developed that did not progress to the degree that the sham-treated animal eyes did over the follow-up period. The in vivo use of a lipid delivery vehicle resulted in a precipitate; however, an effective naked ribozyme dose was identified that did not cause this side effect.

CONCLUSIONS. In addition to validating the newly developed dispase PVR rabbit model, the results indicate that ribozyme targeted against the cell cycle agent PCNA is efficacious in the treatment or prevention of PVR in the rabbit eye. These experiments suggest that chimeric ribozyme targeted against PCNA may have a therapeutic or preventative role in humans.




This article has been cited by other articles:


Home page
Arch OphthalmolHome page
W. M. Schiff, J. C. Hwang, M. D. Ober, J. L. Olson, E. Dhrami-Gavazi, G. R. Barile, S. Chang, N. Mandava, and for the IM-VIT100 Study Group
Safety and Efficacy Assessment of Chimeric Ribozyme to Proliferating Cell Nuclear Antigen to Prevent Recurrence of Proliferative Vitreoretinopathy
Arch Ophthalmol, September 1, 2007; 125(9): 1161 - 1167.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J-H Chen, R Ling, Q Yao, Y Li, T Chen, Z Wang, and K-Z Li
Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model
Endocr. Relat. Cancer, March 1, 2005; 12(1): 93 - 100.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
M. Shiota, M. Sano, M. Miyagishi, and K. Taira
Ribozymes: Applications to Functional Analysis and Gene Discovery
J. Biochem., August 1, 2004; 136(2): 133 - 147.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Association for Research in Vision and Ophthalmology